Phacetoperane - NLS Pharma

Drug Profile

Phacetoperane - NLS Pharma

Alternative Names: NLS-3

Latest Information Update: 08 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroLifeSciences
  • Developer NLS Pharma
  • Class Acetates; Anorectics; Antidepressants; Esters; Piperidines; Small molecules
  • Mechanism of Action Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Attention-deficit hyperactivity disorder; Narcolepsy

Most Recent Events

  • 03 Dec 2015 Phase-I clinical trials in Attention-deficit hyperactivity disorder in France (unspecified route) prior to December 2015
  • 03 Dec 2015 Phase-I clinical trials in Narcolepsy in France (unspecified route)
  • 05 Feb 2015 NeuroLifeSciences has patent protection for phacetoperane in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top